Nonsense mutations cause about 10-12% of cases across over 10,000 rare diseases, impacting roughly 40 million people. These mutations often lead to the most severe disease outcomes.
At Nonsense Tx, we focus on developing small-molecule therapies to boost collagen 7 production for Dystrophic EB patients. 35% of RDEB patients have at least one nonsense mutation.
Early lab results using primary patient cells—tested with a leading expert on nonsense mutations in EB—have shown very promising outcomes
Company Details
- Employees
- 3
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.nonsensetx.com
Nonsense Tx Questions
Nonsense Tx's website is http://www.nonsensetx.com
Nonsense Tx's LinkedIn profile is https://www.linkedin.com/company/nonsense-tx
Nonsense Tx has
3 employees.
View email and phone details for 3
employees at Nonsense Tx.
Nonsense Tx's industry is
Biotechnology Research
Nonsense Tx's top competitors are
Termeer Institute,
Zencargo,
Navega Therapeutics,
Huckletree,
General Projects,
Hydrogene Therapeutics,
Momentum Therapeutics,
Arpelos Biosciences,
Dub Therapeutics,
Abe (Accelerating Breakthroughs In Eb).
Nonsense Tx's categories are Biotechnology Research
Nonsense Tx's founding year is 2023
